Long-term safety and efficacy of BCMA-directed CAR T-cell therapies in multiple myeloma: comparative insights from Cilta-cel, Ide-cel, Anito-cel, and FCARH143.

Reinhardt B, Naing PT, Baljevic M

Open source

DOI
10.21037/tcr-2026-0438
Published
2026 Aug 31
Container
Translational cancer research
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.21037/tcr-2026-0438,
  title = {Long-term safety and efficacy of BCMA-directed CAR T-cell therapies in multiple myeloma: comparative insights from Cilta-cel, Ide-cel, Anito-cel, and FCARH143.},
  author = {Reinhardt B and Naing PT and Baljevic M},
  year = {2026},
  journal = {Translational cancer research},
  doi = {10.21037/tcr-2026-0438},
  url = {https://doi.org/10.21037/tcr-2026-0438}
}

RIS

TY  - JOUR
TI  - Long-term safety and efficacy of BCMA-directed CAR T-cell therapies in multiple myeloma: comparative insights from Cilta-cel, Ide-cel, Anito-cel, and FCARH143.
AU  - Reinhardt B
AU  - Naing PT
AU  - Baljevic M
PY  - 2026
JO  - Translational cancer research
DO  - 10.21037/tcr-2026-0438
UR  - https://doi.org/10.21037/tcr-2026-0438
ER  - 

APA

B, R., PT, N., & M, B. (2026). Long-term safety and efficacy of BCMA-directed CAR T-cell therapies in multiple myeloma: comparative insights from Cilta-cel, Ide-cel, Anito-cel, and FCARH143.. Translational cancer research. https://doi.org/10.21037/tcr-2026-0438

Source records